US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
(CSE:
QNTM
)
4.510
UNCHANGED
Last Price
Updated: 3:15 PM EDT, Sep 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about QNTM
< Previous
1
2
3
4
5
6
Next >
Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials
October 01, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Results of Annual General and Special Meeting
September 29, 2025
Via
Investor Brand Network
Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders
September 29, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025
September 24, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives Health Canada Product License for Qlarity
September 18, 2025
Via
Investor Brand Network
Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance
September 18, 2025
From
Quantum BioPharma
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Licensee Unbuzzd Wellness to Host Investor Webinar on Sept. 16
September 12, 2025
Via
Investor Brand Network
Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT
September 12, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives BUY Rating, $45 Price Target from Kingswood Capital Partners
September 10, 2025
Via
Investor Brand Network
Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target
September 10, 2025
This was unpaid research with no consideration given
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) Provides Corporate Update
August 21, 2025
Via
Investor Brand Network
Quantum BioPharma Announces Corporate Updates
August 21, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) to Seek Shareholder Approval for $600K Private Placement
August 12, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Signs CDMO Agreement for Oral Lucid-MS in Phase 2 MS Trial
August 11, 2025
Via
Investor Brand Network
Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial
August 11, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) PET Tracer Shows Potential for Monitoring Myelin Integrity in Multiple Sclerosis
August 08, 2025
Via
Investor Brand Network
Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients
August 08, 2025
Ongoing Joint Clinical Study Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302
From
Quantum BioPharma
Via
GlobeNewswire
Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of
August 07, 2025
Unprecedented Quarter Shows Company’s Strong Financial Position and Continued Momentum with its Multiple Sclerosis Clinical Trials and unbuzzdTM Recreational Beverage and Alcohol Metabolizer
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Positive Phase 1 Safety Results for Lucid-MS
August 05, 2025
Via
Investor Brand Network
Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)
August 05, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Opposes Motion to Dismiss in $700 Million Market Manipulation Lawsuit
August 04, 2025
Via
Investor Brand Network
Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing
August 04, 2025
From
Quantum BioPharma
Via
GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Portfolio Company Unbuzzd Wellness Launches $5 Million Regulation D Offering
July 31, 2025
Via
Investor Brand Network
Topics
Initial Public Offering
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO
July 31, 2025
This Offering Will Not Dilute Quantum BioPharma Shareholders
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Makes Strategic Investment in GameStop Corp.
July 22, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom
July 08, 2025
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
June 26, 2025
Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise
From
Quantum BioPharma
Via
GlobeNewswire
Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress
June 18, 2025
Los Angeles, California--(Newsfile Corp. - June 18, 2025) - Singular Research, a leading provider of independent research on small-cap companies,...
Via
Newsfile
Topics
Initial Public Offering
Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital
June 17, 2025
Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum’s Investigational MS drug, Lucid-21-302
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds
June 13, 2025
From
Quantum BioPharma
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
